Treatment intensification with autologous bone marrow transplantation (ABMT) was administered to 37 cases of Hodgkin's and @entity1893 ( @entity1733 and @entity1893 ) who were in complete or partial remission (CR or PR) after chemotherapy (MOPP/ABVD or F-MACHOP respectively) and to 12 cases of @entity1733 and @entity1893 who were in relapse. ABMT treatment was BAVC for @entity1893 and BEAM for @entity1733 . Marrow cells were harvested from the marrow and cryopreserved. The number of mononuclear marrow cells that was reinfused ranged between 0.19 and 0.80 x 108/Kg b.w. (median 0.39). All the @entity1 were treated with @entity1261 ( @entity1261 , Filgrastim) at a dose of 5 mg/Kg b.w. from day +4 until the absolute neutrophil count exceeded 1 x109/L for 3 consecutive days. Engraftment was observed in all cases, and no transplant-related @entity204 occurred. The @entity1 with @entity1893 and @entity1733 received a median of 12 (range 2-19) and 14.5 (range 9-27) doses of @entity1261 respectively. Median time to 20 x 109/L platelet count was 14 to 17 days. Median time to an absolute neutrophil count 0.5x109/L was 13 days. A febrile episode during the period of post-transplant aplasia was documented in 35 @entity1 (71%). Fever was associated with Gram+ @entity582 in 31% of the cases and with Gram- @entity582 in 11% of cases. @entity281 was documented in two cases. No @entity364 were recorded. Median hospitalisation time from reinfusion ranged between 19.5 days ( @entity1893 ) and 23 days ( @entity1733 ). Thirty-four of 37 cases (92%) who were transplanted in CR or in PR are currently alive and in continuous CR with a median follow-up time of 37 months after ABMT. Three of 12 cases (25%) who were transplanted in relapse are alive and in CR. Our data point out that ABMT followed by @entity1261 is a safe and a very effective procedure for high risk @entity706 , when ABMT is planned and is performed not as a rescue procedure but when it is integrated in the treatment strategy from the very beginning.

Treatment intensification of XXXX with autologous bone marrow transplantation and @entity1261 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1733 :: ('MESH:C538324', 'Disease') :: ['HL'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony stimulating factor'] @entity706 :: ('MESH:D008223', 'Disease') :: ['malignant lymphomas'] @entity281 :: ('MESH:D007239', 'Disease') :: ['Herpes Simplex infection'] @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infections'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity582 :: ('MESH:C531821', 'Disease') :: ['bacteraemia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity706 :: (MESH:D008223,Disease) :: ['malignant lymphomas']
